Introduction
Acute renal failure (ARF) is de®ned as a rapid deterioration of renal function associated with the accumulation of nitrogenous wastes in the body that is not due to prerenal or postrenal factors. When ARF is not the result of primary vascular, glomerular, or interstitial disorders (approximately 15% of all cases), it has been referred to as acute tubular necrosis (ATN). ATN is caused by ischaemic (50%) or nephrotoxic (35%) injury to the kidney. In 50% of hospital-acquired ARF, however, the cause is multifactorial. The incidence of ATN is particularly high in patients admitted to an intensive care unit (ICU). Unfortunately, neither this incidence nor the morbidity and mortality associated with ATN have declined, despite ongoing improvement in the supportive care of these patients and the advent of intermittent and continuous renal replacement therapy (CRTT) [1±4] . The spectrum of ATN in the ICU, compared with that seen in other settings, is indeed different, with more patients developing ATN predominantly as part of a multiple organ dysfunction syndrome, whereas isolated ARF is the usual presentation in the non-ICU setting [5] .
In an important paper that evaluated 105 patients admitted to ®ve academic trauma centres during a 1-year period, Gill Cryer et al. [6] demonstrated that multiple organ dysfunction syndrome after trauma is established within 24 h of injury in the majority of patients who develop it. Two reviews that described the special circumstances of ARF in the ICU and cardiac care unit have recently been published [7 . . ,8
. . ].
The pathophysiological abnormalities in ARF include changes in the intrarenal haemodynamics, and ischaemic and toxic injury to tubular cells. The interplay of these abnormalities form the basis for the acute decrease in glomerular ®ltration rate, which is the result of intrarenal vasoconstriction with a fall in glomerular ®ltration pressure, tubular obstruction and transtubular backleak of the ®ltrate.
In recent years, research in experimental ATN has focused on the role of intrarenal vasoconstriction by decreased synthesis and release of nitric oxide; increased release of endothelin-1, the most potent vasoconstrictor found in humans [9,10]; and on two major mechanisms of cell injury and the possibilities of attenuating this damage . ,12±19]. The ®rst of these mechanisms pertains to the fate of the individual polarized tubular epithelial cell after injury. After injury, the cell becomes depolar-ized and cell death can occur by either necrosis or apoptosis. If the cell survives, it can initiate a repair programme that will return it to its normal polarized state. This repair presumably follows developmental pathways, and growth and differentiation factors play a role. In the second mechanism tubule cells actively participate in immune and in¯ammatory events, whereby they interact with each other and release a variety of in¯ammatory mediators and cytotoxic substances into their local environment. Much attention has been devoted to damaging effects of free radicals such as oxygen free radicals and nitric oxide, and to the role of neutrophil in®ltration into the renal interstitium and into the renal blood vessels. To what extent some, or all, of these pathophysiological mechanisms play a role in human ATN is of course dif®cult to con®rm, but because human ATN is often multifactorial, all mechanisms may be involved.
This review summarizes the evidence of certain preventive or therapeutic strategies that can be applied in critically ill patients suffering from ATN. Because both the nondialytic (conservative) as well as the dialytic management of such patients are important, a critical evaluation of selected issues of both forms of treatment is provided.
Risk factors for acute renal failure
Risk factors for ARF after coronary intervention (mostly acute contrast nephropathy) have recently been analysed by McCullough et al. [20] . The preintervention creatinine clearance, the presence of diabetes mellitus, and the contrast dose were independent predictors of dialysis-requiring ARF. In a series of 447 consecutive adult patients who required cardiopulmonary bypass [21] , the four most important independent risk factors were preoperative renal insuf®ciency, postoperative hypotension, cardiopulmonary bypass time greater than 140 min and old age. A similar analysis was performed by Conlon et al. [22] . Of 2672 patients who underwent coronary artery bypass grafting, 7.2% developed ARF with 0.7% of these needing dialysis. The mortality in coronary artery bypass grafting patients who required dialysis was 28%, compared with 1.8% among those who did not require dialysis. Variables independently associated with dialysis-requiring ARF included preoperative serum creatinine, duration of cardiopulmonary bypass, presence of a carotid artery bruit and presence of diabetes. In a series of patients with post-traumatic ARF [23 . ], the need for mechanical ventilation with a positive end-expiratory pressure greater than 6 cmH 2 O, rhabdomyolysis with creatine phosphokinase greater than 10 000 IU/l, and haemoperitoneum were the three most strongly associated risk factors for the development of ARF.
Several medications ± notably acyclovir, sulfonamides, methotrexate, indinavir and triamterene ± are associated with the production of crystals that can precipitate in the lumen of the tubules, and thus may lead to ARF [24
]. Renal failure may be reversible if the drug is discontinued, and by volume repletion and alkalinization of the urine when appropriate. ,27]. These drugs can be divided into those that act on haemodynamic factors and those that act against ]. Juste et al.
Nondialytic management
[34] investigated the validity of a low-dose`renal' dopamine regimen in critically ill adult patients by studying steady-state dopamine clearances. Plasma clearance is lower in these patients than in elective surgical patients, and there is a very large interindividual variation. It is therefore impossible to predict plasma levels from the infusion rate of dopamine and the concept of a selective renovascular low-dose dopamine infusion is invalid in critically ill patients.
Some of the drugs discussed above have recently been tested in the prevention of radiocontrast-induced nephropathy (RCIN). Earlier studies of single drug prevention strategies with atrial natriuretic factor, loop diuretics, dopamine, or mannitol [35] showed no clear bene®t over hydration with 0.45% saline alone across a spectrum of patients at risk. A prospective, randomized, controlled, single-blind trial was conducted in which 98 participants were randomized to forced diuresis with intravenous crystalloid plus furosemide, mannitol, or low-dose dopamine or to intravenous crystalloid and matching placebos [36 . . ]. That study suggested that forced diuresis with intravenous crystalloid, furosemide, and mannitol (if haemodynamics permit), beginning at the start of angiography, provides a modest bene®t against RCIN, provided a high urine¯ow rate can be achieved. The ef®cacy of intravenous atrial natriuretic peptide (anaritide, ANP 4±28) in preventing RCIN was carefully investigated in a prospective, randomized, double-blind, placebo-controlled trial in patients with stable chronic renal failure, with or without diabetes mellitus [37] . There were no statistical differences in the incidence of RCIN. Although the patients with diabetes mellitus had a signi®cantly greater incidence of RCIN, no bene®cial effect of anaritide was detected in the diabetic or nondiabetic groups. In a prospective, doubleblind, placebo-controlled study [38] , the effect of the oral administration of theophylline, an adenosine receptor antagonist, was investigated with regard to changes in renal haemodynamics and tubular injury induced by radiocontrast media in 80 well-hydrated patients with pre-existing chronic renal insuf®ciency (creatinine 41.5 mg/dl). The results showed that the glomerular ®ltration rate is preserved by hydration alone in these patients, without further additional bene®t from the administration of theophylline.
The effect of urodilatin on the peak value and course of serum creatinine in critically ill patients with ARF after major abdominal surgery and the necessity for renal replacement therapy (RRT) was recently investigated [39] . Although there was a tendency for a lower peak serum creatinine value in the urodilatin group, the difference did not reach statistical signi®cance. Also the total number of haemodialyses due to oligouria/ anuria or hyperkalaemia was the same in both groups.
An important double-blind, placebo-controlled multicentre study [40 . . ] has explored the effect of subcutaneous administration of recombinant human insulin-like growth factor-I (100 mg/kg desirable body weight, twice per day for up to 14 days) on the enhancement of recovery of renal function in critically ill patients with ARF. Injections were started within 6 days of the onset of ARF. Insulin-like growth factor-I did not accelerate the recovery of renal function in ARF patients with substantial comorbidity.
Dialytic treatment
A number of controversial issues exist in this area. This discussion is limited to a brief review of two issues: the possible impact of the selection of biocompatible or bioincompatible dialysis membranes; and the choice between the CRRTs and the intermittent forms of haemodialysis (IHD).
Biocompatibility of the dialysis membranes
Membrane bioincompatibility issues cover more than complement and leucocyte activation. Other humoral pathways and cellular mechanisms can be activated during dialysis, leading to coagulation disturbances, allergy, leaching and spallation, making the biocompatibility issue more complex than was originally supposed.
Among the dialysis membranes, unsubstituted cellulosic cuprophane obviously imposes the most important complement and leucocyte activation; the remaining cellulosic membranes, even cellulose acetate, induce a less pronounced response. Although the synthetic membranes in general are considered to be more biocompatible, variable degrees of complement activation have been observed. Remarkably, the AN69 membrane appears to be a strong complement activator, but immediately adsorbs the activated complement [41] . Complement activation during the blood±dialyzer interaction with certain, especially unmodi®ed, cellulosic membranes (but not with more compatible membranes) can lead to neutrophil in®ltration into the kidney (and other tissues) and prolonged renal damage [42] .
In older studies [42,43] the use of cuprophane membrane dialyzers had a negative impact on the survival rate of ARF patients, the occurrence of sepsis, the duration of oliguria and the rate of renal recovery compared with the use of biocompatible polymethylmethacrylate or AN69 membrane dialyzers. These bene®ts were limited to patients who were nonoliguric before the onset of haemodialysis. In an analysis by Mehta et al.
[44] of the impact of the biocompatibility of the membranes, patient outcome was markedly better in patients on membranes with high biocompatibility. This relation disappeared, however, after correction for severity of disease (Acute Physiology and Chronic Health Evaluation III score over the entire observation period). Neveu et al.
[45] analysed the prognostic factors in ICU patients with ARF with and without sepsis, and indicated the nature of the membrane as one of the contributing factors to increased mortality. They found that the outcome was more bene®cial for noncuprophane dialyzers.
Two recent studies [46 . . ,47
. . ] analysed some of the factors that in¯uence the incidence of early renal graft function after transplantation. It appeared that the use of bioincompatible haemodialysis membranes or peritoneal dialysis during pretransplant haemodialysis therapy and the application of ultra®ltration within 24 h before kidney transplantation enhance the risk of post-transplantation ARF and early graft dysfunction.
In one of the largest patient populations studied up to now [48], a prospective randomized multicentre evaluation of the outcome (survival and recovery of renal function) in 153 patients was performed. That study covered the 72 patients originally evaluated by Hakim et al.
[43], with an additional 81 patients who were submitted to an identical protocol, and showed a positive effect of the biocompatibility of the membrane on survival and recovery of renal function. Divergent outcomes were virtually con®ned to patients who were nonoliguric at the start of dialysis. Overall trends were the same in all centres involved, and remained present after adjustment for severity of disease.
However, there are some studies, summarized by us [49] , in which a bene®cial effect of biocompatible membranes was not observed. The most recent prospective multicentre European study of the impact of biocompatibility of dialysis membranes on the outcome of patient survival, duration of stay in the ICU, and renal recovery [50
. . ] did not show differences in the outcome parameters between the group of patients dialyzed with bioincompatible cuprophane or biocompatible polymethylmethacrylate membranes.
The effect of dialyzer membranes on protein and amino acid losses has not yet been widely investigated, but in a small crossover study [51] it was shown that amino acid losses with the use of high-¯ux polysulfone membranes exceeded those found with the use of low-¯ux cuprophane membranes.
In spite of the divergent results, however, we feel that there is more evidence that suggests a negative role for complement-activating, bioincompatible membranes on the outcome of ARF than vice versa.
Choice of dialysis modality
Several recent reviews [11 . . ,52 . . ,53
.
,54
. . ] have extensively covered the choice of either IHD or CRRT in critically ill patients with ARF. Continuous therapies incorporate several at least theoretical advantages, such as improved haemodynamic stability, the possibility for unlimited alimentation, optimal¯uid balance and gradual urea removal without¯uctuations. Some of these advantages are not yet fully documented, however, and it has not yet been determined whether they have a signi®cant impact on outcome and prognosis, which is the ultimate measure of treatment ef®ciency.
Many studies have suggested greater haemodynamic stability when CRRT instead of IHD is used [52 . . ,55]. Although statistically signi®cant, the clinical relevance of the observed differences was low (for review [17] ). As far as we know, only one cross-over study has been performed to date [56] and did not ®nd a difference in haemodynamic tolerance of CRRT compared with that of IHD. In that study, the frequencies of drops of mean arterial blood pressure of greater than 10 mmHg were 25 and 26% in CRRT and IHD, respectively; there was also no difference in need for vasopressor treatment.
It is also unknown whether continuous venovenous haemodia®ltration (CVVHDF) provides better control of azotaemia than IHD. In order to study the effect on azotaemic control of changing ARF treatment from IHD to CVVHDF, 47 consecutive critically ill patients with multiorgan failure and ARF treated with IHD and 47 similar patients treated with CVVHDF were studied [57] . Analysis of daily morning urea and creatinine concentrations over the period of RRT in the ICU revealed that CVVHDF was associated with a signi®-cantly lower plasma urea and serum creatinine level at 24 h treatment, despite similar levels at the start of therapy. Throughout the duration of therapy, mean urea levels and mean serum creatinine levels showed signi®cantly better control of uraemia with CRRT. It was concluded that changing the form of RRT from IHD to CRRT is associated with improved control of azotaemia. In this regard, an important study [58 . . ] measured the delivery of dialysis dose in ARF patients, dialyzed with IHD. The conclusion was that bloodbased urea kinetics used to estimate the dose of dialysis provide consistent results, but when compared with dialysate-side kinetics the blood-based method substantially overestimates the amount of solute removal.
Swartz et al. [59
. . ] made an analysis of treatment modality (CVVH versus haemodialysis) in patients with severe ARF based only on the ®rst modality chosen in an intentto-treat manner in order to minimize the effect of patient assignment of other uncontrolled biases or of multiple switches in treatment. All 349 adult patients with ARF receiving RRT during 1995 and 1996 were analysed using multivariate Cox proportional hazards methods. Initial univariate analysis showed the risk of death when receiving initial CVVH to be more than twice that when receiving initial haemodialysis. Progressive exclusion of patients, in whom the RRT modality might not be open to choice and the risk for death was very high, left 227 patients in whom the risk for death was 1.09 (95% con®dence interval 0.67±1.8) for initial CVVH, which is virtually equivalent to the risk with initial haemodialysis. These results show that the high crude mortality rate of patients undergoing CVVH was related to the severity of illness and not to the treatment choice itself. With the addition of more inclusive comorbidity data and a broader spectrum of interim outcomes, this type of analysis is a practical alternative to what would be a cumbersome and costly prospective, controlled trial comparing traditional haemodialysis with CVVH.
Major disadvantages of continuous therapies are the ongoing necessity for continuous anticoagulation, immobilization of the patient, and possible side effects from lactate-containing replacement¯uid or dialysate. On the other hand, CRRT procedures have certainly made the management of critically ill patients easier. In particular, oligoanuric patients with diuretic-resistant volume overload, and haemodynamically unstable patients with ARF and concomitant sepsis or multiorgan failure appear to bene®t most from continuous treatment. Noncritically ill patients with uncomplicated renal failure (e.g. due to the use of dye or antibiotics) can be treated with IHD or peritoneal dialysis. Furthermore, IHD is preferable in patients with haemorrhagic diathesis because it can be easily performed without anticoagulants.
An association between morbidity and mortality from sepsis or multiple organ failure and in¯ammatory cytokines has been suggested by several studies, but strategies aimed at abrogating the effects of proin¯am-matory cytokines, such as tumour necrosis factor-a, interleukin-1a and interleukin-6, in human forms of sepsis have shown equivocal bene®t [60] . There has been interest in examining the effect of CRRT on these cytokines, and successful removal of cytokines with high-volume haemo®ltration or frequent ®lter changes of polyacrylonitrile haemo®lter has been described [61±63]. Our group [64
. . ] was able to show, using an AN69 membrane, that CVVH led to a decrease in the concentration of tumour necrosis factor-a, interleukin1b and interleukin-6. Most of the removal is due to adsorption to the AN69 membrane, and the concentration remains low only for a few hours after a ®lter change [64
. . ]. A decrease in the concentrations of anti-in¯am-matory cytokines such as interleukin-10 and interleukin-1 receptor antagonist was also observed, however. There was no demonstrable relationship between cytokine removal and improved haemodynamic stability. A less sophisticated but similar study was performed by Kellum et al. [65] . Thirteen patients with systemic in¯ammatory response syndrome and ARF were randomized to receive either convective clearance using CVVH or diffusive clearance using CVVHDF for the ®rst 24 h, followed by the other modality for 24 h. Only minimal amounts of mediators were recovered in the ef¯uents with either therapy, except for interleukin-6. Although the clearances for interleukin-6 were different between therapies, these differences did not translate into signi®cant changes in circulating interleukin-6 concentrations. Plasma endotoxin concentrations were not different between therapies.
The main advantages of either IHD or CRRT also represent their major weaknesses; the high ef®ciency of IHD allows short, intermittent therapy, which can potentially lead to haemodynamic intolerance, poor¯uid control and a`saw-tooth' pattern of metabolic control; and low-ef®ciency CRRT assures smooth metabolic control, and perhaps better haemodynamic stability, but neccesitates continuous treatment and thus continuous anticoagulation. For adequate metabolic control with CRRT, high ultra®ltrate volumes are needed, increasing the risk for errors in¯uid balance calculations. The need for large quantities of industry-prepared dialysate, and for specially adapted arti®cial kidney sets make the application of CRRT more expensive than IHD. Conversely, the need for on-line water treatment makes IHD more complicated, but reduces the cost of the treatment. Its intermittent nature also reduces the burden for the nursing and medical staff, and creates time for other diagnostic or therapeutic out-of-unit procedures, which are often needed in this type of patient.
It is thus not surprising that`hybrid techniques' have emerged to provide alternative answers in the polarized discussion between IHD and CRRT. These`slow, extended daily dialysis' techniques all combine the advantages of CRRT and IHD by using a dialysis monitor and water treatment module for on-line production of dialysate to perform slow, but extended and daily haemodialysis. Until now, no large-scale studies are available on slow, extended daily dialysis; however, the technique is increasingly being used, and the ®rst preliminary reports are positive [66, 67] . In our experience, the use of a single type of machine, the associated reduction of the workload and the intermittent nature make slow, but extended, daily dialysis very acceptable for the ICU nursing team.
Conclusion
Other than for correction of a disturbed circulation or volume depletion, or where possible a moderate overexpansion of the extracellular volume, there is little or no evidence that any of the pharmacological interventions discussed above are of proven and consistent ef®cacy in the prevention or treatment of ATN. The present options available to the clinician for the treatment of a patient with established ATN are limited to the following: institution of supportive dialytic interventions; providing nutritional support to these often very ill patients; avoiding or treating the life-threatening complications, such as hyperkalaemia and other severe electrolyte or acid±base disturbances, pulmonary oedema and infections; and passively awaiting the regeneration of the renal epithelium and its functional recovery.
The dialysis treatment modality of choice for ARF in the ICU patient remains a matter of controversy. In many centres, this controversy is enhanced by the con¯ict of interest between the ICU and the nephrology department. Furthermore, it is our impression that for intermittent as well as for continuous dialysis modalities, modi®cations of these techniques remain unused. This lack of¯exibility in adapting the dialysis techniques to the individual needs of the patients limits their effect and ef®ciency. It is our opinion that all dialysis strategies should be mastered and utilized in the appropriate indications in the ICU patients. So far, no hard evidence is available that one technique above another is superior, if they are used for the correct indications and applied by a skilled ICU and dialysis team. 403±411. This study suggests that forced diuresis with intravenous crystalloid, furosemide, and mannitol (if haemodynamics permit) and beginning at the start of angiography provides a modest benefit against RCIN, provided a high urine flow rate can be achieved.
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